Literature DB >> 17029602

Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice.

Beatrice A Girard1, Vincent Lelievre, Karen M Braas, Tannaz Razinia, Margaret A Vizzard, Yevgeniya Ioffe, Rajaa El Meskini, Gabriele V Ronnett, James A Waschek, Victor May.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are closely related neurotrophic peptides of the secretin/glucagon family. The two peptides are derived from a common ancestral gene and share many functional attributes in neuronal development/regeneration which occur not only from overlapping receptor subtype signaling but also through common mechanisms regulating their expression. Although PACAP or VIP null mice have been generated for study, it is unclear whether the expression of the complementary peptide or their receptor systems are altered in a compensatory manner during nervous system development. By radioimmunoassay and quantitative PCR measurements, we first show that PACAP and VIP have very different temporal patterns of expression in developing postnatal mouse brain. In wild-type animals, PACAP transcript and peptide levels increased rapidly 2- and 5-fold, respectively, within 1 week of age. These levels at 1 week of age were maintained through adulthood. VIP transcript and peptide levels, by contrast, increased 25- and 50-fold, respectively, over a later time course. In parallel studies of development, there were no apparent compensatory increases in brain VIP expression in the PACAP knockout animals, PACAP expression in the VIP-deficient animals, or receptor mRNA levels in either genotype. To the contrary, there was evidence for developmental delays in the expression of peptide and receptor transcripts in the knockout animals. A series of behavioral and neurological tests demonstrated differences between the knockout genotypes, revealing some functional distinctions between the two genes. These results suggest that the PACAP and VIP have evolved to possess distinct biological activities and intimate that the respective knockout phenotypes represent deficits unmitigated by the actions of the complementary related peptide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17029602     DOI: 10.1111/j.1471-4159.2006.04112.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  44 in total

1.  Microarray analyses of pituitary adenylate cyclase activating polypeptide (PACAP)-regulated gene targets in sympathetic neurons.

Authors:  Karen M Braas; Kristin C Schutz; Jeffrey P Bond; Margaret A Vizzard; Beatrice M Girard; Victor May
Journal:  Peptides       Date:  2007-04-19       Impact factor: 3.750

2.  Bladder dysfunction and altered somatic sensitivity in PACAP-/- mice.

Authors:  Victor May; Margaret A Vizzard
Journal:  J Urol       Date:  2010-02       Impact factor: 7.450

3.  Vasoactive intestinal peptide is critical for circadian regulation of glucocorticoids.

Authors:  Dawn H Loh; Catalina Abad; Christopher S Colwell; James A Waschek
Journal:  Neuroendocrinology       Date:  2008-06-19       Impact factor: 4.914

4.  Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice.

Authors:  Simon Studeny; Bopaiah P Cheppudira; Susan Meyers; Elena M Balestreire; Gerard Apodaca; Lori A Birder; Karen M Braas; James A Waschek; Victor May; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

5.  PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis.

Authors:  Beatrice M Girard; Amanda Wolf-Johnston; Karen M Braas; Lori A Birder; Victor May; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-06-19       Impact factor: 3.444

6.  PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress.

Authors:  Michael L Lehmann; Tomris Mustafa; Adrian M Eiden; Miles Herkenham; Lee E Eiden
Journal:  Psychoneuroendocrinology       Date:  2012-10-11       Impact factor: 4.905

7.  Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in anxiety-like behavior.

Authors:  Sayamwong E Hammack; Joseph Cheung; Kimberly M Rhodes; Kristin C Schutz; William A Falls; Karen M Braas; Victor May
Journal:  Psychoneuroendocrinology       Date:  2009-01-31       Impact factor: 4.905

8.  Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.

Authors:  Eliezer Giladi; Joanna M Hill; Efrat Dresner; Conor M Stack; Illana Gozes
Journal:  J Mol Neurosci       Date:  2007-10-02       Impact factor: 3.444

9.  Pro- and anti-mitogenic actions of pituitary adenylate cyclase-activating polypeptide in developing cerebral cortex: potential mediation by developmental switch of PAC1 receptor mRNA isoforms.

Authors:  Yan Yan; Xiaofeng Zhou; Zui Pan; Jianjie Ma; James A Waschek; Emanuel DiCicco-Bloom
Journal:  J Neurosci       Date:  2013-02-27       Impact factor: 6.167

10.  Parabrachial nucleus (PBn) pituitary adenylate cyclase activating polypeptide (PACAP) signaling in the amygdala: implication for the sensory and behavioral effects of pain.

Authors:  Galen Missig; Carolyn W Roman; Margaret A Vizzard; Karen M Braas; Sayamwong E Hammack; Victor May
Journal:  Neuropharmacology       Date:  2014-07-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.